Aphria Inc. joins Shoppers Drug Mart and TruTrace Technologies Pilot Program for Medical Cannabis Verification

Aphria加入Shoppers Drug Mart和TruTrace试验计划,进行医用大麻验证

2019-09-06 09:00:06 CFN Media Group

本文共2279个字,阅读需6分钟

Aphria Inc. and TruTrace Technologies Inc.   today announced that Aphria has joined Phase 2 of the Shoppers Drug Mart medical cannabis verification pilot program . The blockchain-secured Pilot Program is specifically designed to increase transparency, interoperability and product identification within the medical cannabis industry. The Pilot Program uses TruTrace’s StrainSecure™ technology as a central hub for identity management, asset tracking, validation, and product authentication. StrainSecure also serves as a master registry for standardized testing, product verification, and quality assurance. First announced by Shoppers in June at the second annual World Cannabis Congress in Saint John, New Brunswick, the Pilot Program is expected to help researchers and clinicians match therapeutic outcomes to specific genetic and chemical profiles, and provide physicians, pharmacists, and patients with greater confidence in the products they prescribe or consume. “We are thrilled to partner with Shoppers Drug Mart and TruTrace Technologies to increase transparency within the medical cannabis industry,” said Irwin D. Simon. “At Aphria Inc., we take responsibility to heart and recognize the importance of standardized testing and quality assurance. This program reflects our ongoing commitment to protecting the health and safety of our patients.” Shoppers recently announced the successful completion of Phase 1 of the Pilot Program and the addition of Deloitte Canada LLP in a project management and advisory role to execute Phase 2. Full production and implementation is targeted for late November 2019. “The participation of a major licensed producer like Aphria, with their expertise and dedication to medical patients, is essential to the success of the Pilot Program,” said TruTrace Technologies CEO Robert Galarza. “Together we are working to develop a unified approach to medical cannabis standards that will help ensure full traceability and consistent patient outcomes.” Under the StrainSecure™ program, the TruTrace team collects plant testing data and performs genomic verification in plant batches which are then registered in a blockchain-enabled database for intellectual property protection and strain validation. All information gathered from the plants, including their molecular and chemical makeup, can be tracked via the program. About Aphria Aphria Inc. is a leading global cannabis company driven by an unrelenting commitment to our people, the planet, product quality and innovation. Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria Inc. has been a leader in low-cost production of high-quality cannabis at scale, grown in natural conditions. Focusing on untapped opportunities and backed by the latest technologies, Aphria Inc. is committed to bringing breakthrough innovation to the global cannabis market. The Company’s portfolio of brands is grounded in expertly-researched consumer insights designed to meet the needs of every consumer segment. Aphria Inc. drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion, with a presence in more than 10 countries across 5 continents. For more information, visit: aphriainc.com About TruTrace Technologies: TruTrace Technologies has developed the first integrated blockchain platform to register and track intellectual property in the cannabis industry. TruTrace’s technology allows cannabis growers and breeders to identify and secure rights to their intellectual property. It also streamlines the administrative process and reduces the costs of genetic and mandatory quality-control testing for legal cannabis. TruTrace’s technology is proprietary, immutable and cryptographically secure, thereby establishing an accurate and permanent account for cannabis strains from ownership to market. Disclaimer for Forward-Looking Information This news release includes forward-looking information within the meaning of Canadian and U.S. securities legislation, concerning the business of TruTrace and Aphria’s participation in the Pilot Program, including statements regarding: the Pilot Program, including its intended scope, characteristics, and perceived benefits; the ability of TruTrace Technologies’ platform to increase transparency, interoperability and product identification within the medical cannabis industry; that the initiative should allow researchers and clinicians to match therapeutic outcomes to specific genetic and chemical profiles, and provide physicians, pharmacists, and patients with greater confidence in the products they prescribe or consume; and that Phase 2 of the Pilot Program is expected to be completed by November 2019, followed by full production and implementation. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that it will prove to be correct and actual results and future events could differ materially from those anticipated in such information. Forward-looking information necessarily involves known and unknown risks, including, without limitation, risks associated with: general economic conditions; adverse industry events; loss of markets; future legislative and regulatory developments in Canada, the United States, and elsewhere; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; and other risks beyond the Company’s control. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company. Readers are cautioned not to place undue reliance on any forward-looking information contained in this news release. Forward-looking information contained in this news release is provided as of the date of this news release. The Company disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. SOURCE TruTrace Technologies Inc. For further information: Aphria Inc.: Media: Tamara Macgregor, Vice President, Communications & Public Affairs, 437-343-4000, [email protected]; Investors: Katie M. Turner, ICR, Inc. 646-277-1228, [email protected]; TruTrace Technologies Inc: Robert Galarza, Chief Executive Officer and Director; Media Relations: Corey Herscu, RNMKR Agency, 416-300-3030; Investor Inquiries: Swapan Kakumanu, Chief Financial Officer, 844-656-3629, [email protected]
Aphria Inc .和 TruTrace Technologies Inc .今天宣布, Aphria 已加入 Shoppers Drug Mart 医用大麻验证试点项目的第2阶段。区块链安全试点计划是专门为提高医用大麻行业的透明度、互操作性和产品识别而设计的。 试点计划使用 TruTrace 的 StrainSecure ™技术作为身份管理、资产跟踪、验证和产品认证的中心枢纽。StrainSecure 还作为标准化测试、产品验证和质量保证的主注册中心。 今年6月,购物者在新不伦瑞克州圣约翰举行的第二届世界大麻大会上首次宣布了试点计划,预计该计划将帮助研究人员和临床医生将治疗结果与特定的基因和化学特征相匹配,并为医生、药剂师、以及对其处方或消费的产品有更大信心的患者。 “我们很高兴与 Shoppers Drug Mart 和 TruTrace Technologies 合作,以提高医用大麻行业的透明度,” Irwin D . Simon 说。“在 Aphria 公司,我们要对心脏负责,并认识到标准化测试和质量保证的重要性。这个计划反映了我们对保护病人健康和安全的持续承诺。” 最近,购物者宣布成功完成第一阶段的试点计划,并增加德勤加拿大有限责任公司在项目管理和咨询作用执行第二阶段。全面生产和实施的目标是2019年11月下旬。 TruTrace Technologies 首席执行官罗伯特•加拉扎( Robert Galarza )表示:“ Aphria 等大型特许生产商的参与,以及他们对医疗患者的专业知识和奉献精神,对于试点项目的成功至关重要。”“我们共同致力于制定统一的医疗大麻标准方法,以帮助确保充分的可追溯性和一致的患者结果。” 在 StrainSecure ™计划下, TruTrace 团队收集植物测试数据,并以植物批次进行基因组学验证,然后在支持区块链的数据库中注册,用于知识产权保护和菌株验证。从植物中收集到的所有信息,包括它们的分子和化学成分,都可以通过程序进行跟踪。 关于 Aphria Aphria Inc .是一家领先的全球大麻公司,以对人类、地球、产品质量和创新的坚定承诺为动力。Aphria Inc .总部位于加拿大温室之都安大略省的莱明顿,是在自然条件下生产高质量大麻的低成本生产领域的领导者。Aphria Inc .专注于尚未开发的机遇,在最新技术的支持下,致力于为全球大麻市场带来突破性创新。公司的品牌组合建立在专门研究的消费者洞察力基础上,旨在满足每个消费者细分市场的需求。Aphria Inc .通过创新、战略伙伴关系和全球扩张的多元化方式,在5大洲的10多个国家开展业务,推动可持续的长期股东价值。有关详细信息,请访问: apriainc.com 关于 TruTrace 技术: TruTrace Technologies 公司开发了第一个用于大麻行业知识产权注册和跟踪的集成区块链平台。TruTrace 的技术允许大麻种植者和饲养者识别并保护其知识产权。它还简化了行政程序,降低了对合法大麻进行遗传和强制性质量控制测试的成本。TruTrace 的技术是专有的、不可变的和密码安全的,从而建立了大麻从所有权到市场的准确和永久的帐户。 有关前瞻性资料的免责声明 本新闻稿包括加拿大和美国证券立法意义内的前瞻性信息,涉及 TruTrace 和 Aphria 参与试点计划的业务,包括关于:试点计划的声明,包括其预期范围、特征以及预期的好处; TruTrace Technologies 平台提高医用大麻行业透明度、互操作性和产品识别能力;该举措应使研究人员和临床医生能够将治疗结果与特定的遗传和化学概况相匹配,并向医生、药剂师提供以及对其处方或消费的产品有更大信心的患者;预计试点计划第二阶段将于2019年11月完成,随后全面生产和实施。尽管本公司认为该等前瞻性资料所依据的预期及假设是合理的,不应过分依赖前瞻性信息,因为本公司无法保证其将被证明是正确的,且实际结果和未来事件可能与此类信息中预期的结果存在重大差异。前瞻性信息必然涉及已知和未知的风险,包括但不限于与以下相关的风险:一般经济条件;不利的行业事件;市场损失;加拿大、美国未来的立法和监管发展;和其他方面;无法从内部和外部来源获得足够的资本,和/或无法以优惠条件获得足够的资本;以及公司无法控制的其他风险。由于许多已知和未知的风险、不确定性和其他因素,其中许多因素无法控制,事件或情况可能导致实际结果与预测结果存在重大差异。读者应注意不要过度依赖本新闻稿中的任何前瞻性信息。本新闻稿中包含的前瞻性信息截至本新闻稿发布之日提供。除适用的证券法律要求外,本公司不承担因新信息、未来事件或结果或其他原因而公开更新任何前瞻性信息的任何意图或义务。 SOURCE TruTrace Technologies Inc . 更多信息: Aphria 公司:媒体: Tamara Macgregor ,副总裁,通信和公共事务,437-343-4000,[电子邮件保护];投资者: Katie M . Turner , ICR , Inc .646-277-1228,[电子邮件保护]; TruTrace 技术公司: Robert Galarza ,首席执行官兼董事;媒体关系: Corey Herscu , RNMKR 代理,416-300-3030;投资者问询: Swasan Kakumani ,首席财务官,844-656-3629,[电子邮件受保护]

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文